Read the article: https://www.genengnews.com/topics/artificial-intelligence/secure-ai-collaboration-will-fine-tune-openfold3-with-proprietary-data/
In a new initiative by the AI Structural Biology (AISB) Consortium and powered by Apheris, OpenFold3, a protein structure prediction algorithm developed by the lab of Mohammed AlQuraishi, will be fine-tuned using proprietary data from AbbVie and Johnson & Johnson.

Read the article: https://www.genengnews.com/topics/artificial-intelligence/secure-ai-collaboration-will-fine-tune-openfold3-with-proprietary-data/

GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.

ADMET liabilities drive 40–45% of clinical attrition, and models break on novel chemistry which is precisely where chemists need them most. Pre-competitive federated networks address this through complementary data collaboration. A walk through the evidence behind the Apheris ADMET Network.

We rebuilt the SandboxAQ affinity head inside ApherisFold and fine-tuned it on 49 JAK2 macrocycles. Architectural changes alone lifted Spearman ranking from 0.418 to 0.60; fine-tuning then pushed validation Pearson from 0.23 to 0.76, mostly by correcting how the model handled inactives.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.

Robin Röhm
Co-Founder & CEO
© 2026 Apheris AI GmbH. All rights reserved.